ADVICENNE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 EUR | +0.59% |
|
-2.06% | -35.71% |
| Apr. 08 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 25 | Advicenne: ODD designation in cystinuria | CF |
| Sales 2024 * | 4.2M 4.5M | Sales 2025 * | 5.75M 6.15M | Capitalization | 20.88M 22.35M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -7.49M | Net income 2025 * | 22M 23.55M | EV / Sales 2024 * | 10.4 x |
| Net Debt 2024 * | 22.7M 24.29M | Net cash position 2025 * | 3.2M 3.42M | EV / Sales 2025 * | 3.07 x |
| P/E ratio 2024 * |
-2.66
x | P/E ratio 2025 * |
0.83
x | Employees | 21 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.22% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.24% | ||
| 1 week | -2.86% | ||
| Current month | -18.46% | ||
| 1 month | -26.26% | ||
| 3 months | -12.94% | ||
| 6 months | -1.97% | ||
| Current year | -36.24% |
1 week
1.65
1.81
1 month
1.553.06
Current year
1.103.08
1 year
1.104.40
3 years
1.1014.30
5 years
1.1016.25
10 years
1.1016.25
| Managers | Title | Age | Since |
|---|---|---|---|
Didier Laurens
CEO | Chief Executive Officer | 59 | 21-05-02 |
| Chief Tech/Sci/R&D Officer | - | 23-03-31 | |
André Ulmann
BRD | Director/Board Member | - | 17-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 11-04-28 | |
Catherine Dunand
BRD | Director/Board Member | 62 | 17-03-08 |
Didier Laurens
CEO | Chief Executive Officer | 59 | 21-05-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.71 | +0.59% | 25 060 |
| 24-04-24 | 1.7 | -0.58% | 20,471 |
| 24-04-23 | 1.71 | +0.23% | 33,442 |
| 24-04-22 | 1.706 | +0.95% | 18,055 |
| 24-04-19 | 1.69 | -3.21% | 21,252 |
Real-time Euronext Paris, April 25, 2024 at 08:44 am EDT
More quotes
Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children.
At the end of 2023, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.7
EUR
Average target price
6.9
EUR
Spread / Average Target
+305.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.24% | 22.31M | |
| -2.86% | 87.31B | |
| +3.95% | 40.86B | |
| -21.94% | 29.36B | |
| +56.40% | 24.49B | |
| -5.41% | 17.31B | |
| -44.23% | 11.26B | |
| -17.60% | 11.62B | |
| -13.96% | 11.31B | |
| +6.29% | 8.31B |
- Stock Market
- Equities
- ALDVI Stock
